Double-blind Placebo-controlled Phase 2 Clinical Trial of TAP-144-SR (3M) in patients with Spinal and Bulbar Muscular Atrophy (SBMA)

Trial Profile

Double-blind Placebo-controlled Phase 2 Clinical Trial of TAP-144-SR (3M) in patients with Spinal and Bulbar Muscular Atrophy (SBMA)

Completed
Phase of Trial: Phase II

Latest Information Update: 13 Jun 2017

At a glance

  • Drugs Leuprorelin (Primary)
  • Indications Muscular atrophy
  • Focus Therapeutic Use
  • Acronyms JASMITT-2
  • Most Recent Events

    • 06 Jun 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top